Trials / Completed
CompletedNCT04740827
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants With Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 315 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atogepant 60 mg | Atogepant tablets. |
| DRUG | Placebo | Atogepant matching placebo tablets. |
Timeline
- Start date
- 2021-03-05
- Primary completion
- 2022-08-04
- Completion
- 2022-08-04
- First posted
- 2021-02-05
- Last updated
- 2023-09-21
- Results posted
- 2023-09-21
Locations
114 sites across 15 countries: United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russia, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04740827. Inclusion in this directory is not an endorsement.